EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous cancer cell line, EB1089 was noted to reverse hypercalcemia. Additionally, EB1089 was reported to downregulate PTHRP expression in a prostate cancer cell line, C4-2 and was also noted to augment anchorage-independent cell growth in vitro. Other studies note that EB1089 inihibits the proliferation of HEp-2 cell lines and is reported that p57 has a profound role in this inhibition. Futhermore, EB1089 is also reported to be a noted mitogen of neonatal rat lung fibroblasts.
1. Abdaimi, K., et al. 1999. Cancer Res. 59: 3325-3328. PMID: 10416587
2. Lu , L., et al. 2008. Mol. Cancer Ther. 7: 1268-1274. PMID: 18483314
3. Ormerod, A.K., et al. 2008. Exp. Lung. Res. 34: 155-182. PMID: 18432454
4. Bhatia, V., et al. 2009. Mol. Cancer Ther. 8: 1787-1798. PMID: 19584236
See how others have used EB 1089. Click on the entry to view the PubMed entry .
PMID: # 27327272 Bartonkova, I. et al. 2016. Chem. Res. Toxicol.
PMID: # 25641222 Wang, K. et al. 2015. Histopathology. 67: 386-97.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.